| __timestamp | Agios Pharmaceuticals, Inc. | Novavax, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 19928000 |
| Thursday, January 1, 2015 | 35992000 | 30842000 |
| Friday, January 1, 2016 | 50714000 | 46527000 |
| Sunday, January 1, 2017 | 71124000 | 34451000 |
| Monday, January 1, 2018 | 114145000 | 34409000 |
| Tuesday, January 1, 2019 | 132034000 | 34417000 |
| Wednesday, January 1, 2020 | 149070000 | 145290000 |
| Friday, January 1, 2021 | 121445000 | 298358000 |
| Saturday, January 1, 2022 | 121673000 | 488691000 |
| Sunday, January 1, 2023 | 119903000 | 468946000 |
Unveiling the hidden dimensions of data
In the ever-evolving landscape of biotechnology, understanding financial trends is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Agios Pharmaceuticals and Novavax from 2014 to 2023. Over this period, Agios Pharmaceuticals saw a steady increase in SG&A expenses, peaking in 2020 with a 680% rise from 2014. Meanwhile, Novavax experienced a dramatic surge, especially from 2020 onwards, with expenses skyrocketing by over 2,250% by 2022. This sharp increase coincides with Novavax's pivotal role in the COVID-19 vaccine race, highlighting the financial demands of rapid scaling. By 2023, Novavax's SG&A expenses were nearly four times those of Agios, reflecting its expanded operations. These trends underscore the financial dynamics of biotech firms as they navigate innovation and market demands.
Merck & Co., Inc. and Novavax, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Novavax, Inc. Trends and Insights
GSK plc and Novavax, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Alnylam Pharmaceuticals, Inc. and Novavax, Inc.
Breaking Down SG&A Expenses: Biogen Inc. vs Novavax, Inc.
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Novavax, Inc.
Selling, General, and Administrative Costs: Alpine Immune Sciences, Inc. vs Agios Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Verona Pharma plc or Novavax, Inc.
Comparing SG&A Expenses: Bausch Health Companies Inc. vs Agios Pharmaceuticals, Inc. Trends and Insights
Merus N.V. vs Novavax, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Arrowhead Pharmaceuticals, Inc. vs Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Protagonist Therapeutics, Inc. vs Novavax, Inc.